Click Therapeutics Announces CT-132 Met Primary Endpoint for the Reduction of Monthly Migraine Days in ReMMi-D Pivotal Trial

portfolio company news
Written By Megan Prock McGrath

Click Therapeutics, Inc., a leader in Digital Therapeutics™ as prescription medical treatments, today announced meeting the primary endpoint in the pivotal randomized, double-blind, controlled, decentralized, study of CT-132 for the preventive treatment of migraine, ReMMi-D (Reduction in Monthly Migraine Days, NCT05853900).

Megan Prock McGrath
Previous

LetsGetChecked Completes Acquisition of Truepill
Next

Mind Medicine Inc. Announces Pricing of Public Offering